Tai Junhu, Lee Kijeong, Kim Tae Hoon
Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, Seoul 02841, Korea.
Pharmaceutics. 2021 Feb 10;13(2):246. doi: 10.3390/pharmaceutics13020246.
Chronic rhinosinusitis is an upper respiratory disease during which topical drug treatment via the nasal cavity is the most actively utilized therapeutic strategy. In addition to steroids, antibiotics, and antifungal agents, which are widely used in clinical practice, research on novel topical agents to improve the bacterial biofilm or mucociliary clearance remains ongoing. Moreover, owing to the complex structure of the nasal cavity, the effects of nasal drug delivery vary depending on factors related to delivery fluid dynamics, including device, volume, and compounds. In this article, we review methods and compounds that have been applied to chronic rhinosinusitis management and introduce recent advances and future perspectives in nasal drug delivery for upper respiratory diseases.
慢性鼻-鼻窦炎是一种上呼吸道疾病,在此期间,经鼻腔局部用药治疗是最积极采用的治疗策略。除了临床实践中广泛使用的类固醇、抗生素和抗真菌药物外,关于改善细菌生物膜或黏液纤毛清除功能的新型局部用药的研究仍在进行中。此外,由于鼻腔结构复杂,鼻腔给药的效果因与给药流体动力学相关的因素而异,包括器械、体积和化合物等。在本文中,我们综述了已应用于慢性鼻-鼻窦炎治疗的方法和化合物,并介绍了上呼吸道疾病鼻腔给药的最新进展和未来展望。